TB R&D Weekly Update: Podcast interview with Dr. Gyanu Lamicchane

Gyanu Lamicchane
Gyanu Lamicchane

Listen to Gyanu Lamicchane Podcast

Summary: Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years.

Dr. Lamichhane has discovered the key role of enzyme L,D-transpeptidase in forming chemical linkages inside the protective cell wall in Mycobacterium tuberculosis, the bacterium responsible for TB diseases. The same enzyme and chemical linkages help hold together the cell walls of other disease-causing bacteria, including salmonella, Enterococcus and Escherichia coli. In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane’s motivation to work with TB.

Additional Coverage:

NIH Director’s Awards Go to Three Johns Hopkins Scientists for Work That Challenges the Status Quo and Speeds Translation of Research

NIH Director’s Awards go to three JHU scientists for work that challenges status quo, speeds translation of research

WGND Interview with Gyanu Lamicchane (May 13, 2010)

Additional TB R&D News:

Lack of Adherence to Isoniazid Chemoprophylaxis in Children in Contact with Adults with Tuberculosis in Southern Ethiopia

Paediatric tuberculosis: out of the dark

Lupin challenges tuberculosis drug price fixed by National Pharmaceutical Pricing Authority

ZAMSTAR study: community counseling cheap, effective way to combat TB

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...